French biosimilar substitution plan alarms pharma; FDA green-lights Vanda's Hetlioz; Novartis sends malaria treatments to Zambia;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton

@EricPFierce: Sources tell Economic Times that Sun will phase out Ranbaxy brand in U.S. Sun doesn't deny it. More | Follow @EricPFierce

@CarlyHFierce: Hamburg to pharma at PhRMA 14, on improving applications: "One message, and I maybe will come to regret it, is really do reach out and engage with us." | Follow @CarlyHFierce

> France has worried pharma with a measure allowing pharmacists to substitute prescribed brand-name biologic drugs with biosimilars. Report

> The FDA has approved Hetlioz, Vanda Pharmaceuticals' ($VNDA) treatment for non-24-hour sleep-wake disorder. Release

> A Florida federal jury has decided that Novartis ($NVS) didn't fail to sufficiently warn a prescribing physician of the risk of jaw injuries supposedly caused by bone drugs Aredia and Zometa. More (sub. req.)

> Two New Jersey men who made hundreds of thousands of dollars trading with insider info on Celgene ($CELG) are headed to federal prison. Story

> An FDA advisory committee recently looked favorably on two competitors to Pfizer's ($PFE) Zyvox, which boasts a $1.4 billion market. More

> Novartis ($NVS) plans to provide two million pediatric antimalarials to Zambia. News

Medical Device News

@FierceMedDev: Boston Scientific eyes Israel in global marketing push. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Adaptive Biotechnologies raises $120M to bolster its immune Dx. Article | Follow @VarunSaxena2

@EmilyWFierce: U.S. and European docs want to put the kibosh on renal denervation devices. Story | Follow @EmilyWFierce

@MichaelGFierce: ICYMI from FierceDrugDelivery: Nanoballoons 'pop' open to deliver cancer drugs when hit with a red laser. Story | Follow @MichaelGFierce

> Abbott creeps toward the FDA with its dissolvable stent. More

> Tendyne raises $25M in Series C financing for mitral valve device. Article

Biotech News

@FierceBiotech: Biogen's hemophilia hopeful scores a PhIII win as FDA awaits. News | Follow @FierceBiotech

@JohnCFierce: Celladon's heart drug grabs 'breakthrough' status at FDA. Item | Follow @JohnCFierce

@DamianFierce: As $GILD gets pilloried over pricing, $BMY (Article) and $MRK (Story) creep up in hep C. | Follow @DamianFierce

@EmilyMFierce: WHO offers road map for new vaccine introduction. Article | Follow @EmilyMFierce

> Soon after media storm fades, Chimerix CEO Moch is out the door. More

Pharma Manufacturing News

> Neuland opens API plant as part of its partnership with Mitsubishi. More

> Kyowa Hakko Kirin finishes $60M biologics API plant. Story

> Sources: Sun has blueprint for turning Ranbaxy around. Article

> AbbVie partners with Arabio for production in Saudi Arabia. More

> Novartis' government-backed vaccine plant should be operational by 2017. Item

Vaccines News

> Merck KGaA lung cancer vaccine gets a second shot with start of PhIII trial. Story

> Colorado Senate hears vaccine bill testimony. Item

> Report: Emergency flu vaccine manufacturing site will be online by 2017. Article

> Novartis' Bexsero wins FDA 'breakthrough' status. More

And Finally... Eye doctors say their profits are smaller than Medicare makes them look. Report (sub. req.)

 

 

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.